Aptabio Therapeutics, Inc.

As of June 30, 2026, Aptabio Therapeutics, Inc. carries a market capitalization of 129.51B, placing it among publicly traded companies globally. Its enterprise value stands at 118.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Aptabio Therapeutics, Inc. has 28.09M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 26.63, and the price-to-book ratio stands at 3.07.

These figures are as of June 30, 2026. The EV/Sales ratio of 24.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 118.70B versus a market cap of 129.51B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Aptabio Therapeutics, Inc. maintains a current ratio of 2.54, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.64, indicating elevated leverage, while an interest coverage ratio of -21.63 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Aptabio Therapeutics, Inc. posted a negative return on equity (ROE) of -33.15, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -23.96, reflecting losses generated across the asset base. The company generates approximately 112.50M in revenue per employee across its workforce of 42.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.35 indicates how many times Aptabio Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Aptabio Therapeutics, Inc. recorded 1.01B in income tax expense. The company reported a pretax loss of -13.86B and -14.87B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Aptabio Therapeutics, Inc.'s stock has declined approximately 14.99% over the past 52 weeks. The 50-day moving average sits at 6,583.80, while the 200-day moving average is 6,678.23.

Over the twelve months ended June 30, 2026, Aptabio Therapeutics, Inc. generated 4.75B in revenue and converted that into -14.87B in net income, yielding earnings per share of -541.63. EBITDA reached -18.31B, while operating income came in at -18.76B.

As of June 30, 2026, Aptabio Therapeutics, Inc. holds 15.73B in cash and equivalents against 4.91B in total debt, resulting in a net debt position of -9.90B. Total book value stands at 42.20B, with working capital of 13.68B providing operational flexibility.

Aptabio Therapeutics, Inc. produced -17.37B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -30.87M in capital expenditures, free cash flow totaled -17.40B - equivalent to -633.95 per share.

Over the twelve months ended June 30, 2026, Aptabio Therapeutics, Inc. posted a gross margin of 48.09, reflecting its pricing power and cost economics. The operating margin of -394.74 and net profit margin of -312.83 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -13.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.15, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Aptabio Therapeutics, Inc. shareholders.

Aptabio Therapeutics, Inc.'s most recent stock split took place on August 24, 2021 with a 1:2 split ratio.

As of June 30, 2026, Aptabio Therapeutics, Inc. has an Altman Z-Score of 2.15, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.